Influenza vaccine effectiveness in Europe: Results from the 2022–2023 VEBIS (Vaccine Effectiveness, Burden and Impact Studies) primary care multicentre study

Marine Maurel, Silke Buda(Robert Koch Institute), Mariëtte Hooiveld(Netherlands Institute for Health Services Research), Mihaela Lazăr, Lisa Domegan(Health Service Executive), Marlena Kaczmarek(European Centre for Disease Prevention and Control), Alina Elena Ivanciuc, Jesús Castilla(Instituto de Salud Pública de Navarra), Verónica Gomez(National Institute of Health Dr. Ricardo Jorge), Gergő Túri(Semmelweis University), Tove Samuelsson Hagey(Public Health Agency of Sweden), Ana Martı́nez(Consejo Superior de Investigaciones Científicas), Esther Kissling, Gloria Pérez‐Gimeno(Instituto de Salud Carlos III), Ana Paula Rodrigues(Microsoft (Brazil)), Frederika Dijkstra(National Institute for Public Health and the Environment), Vincent Enouf(Université Claude Bernard Lyon 1), Maria Elena Mihai, Adam Meijer(National Centre for Infectious Diseases), Aryse Melo(National Institute of Health Dr. Ricardo Jorge), Beatrix Oroszi, Francisco Pozo(Instituto de Salud Carlos III), Ralf Dürrwald(IDT Biologika (Germany)), J Horváth(Semmelweis University), Luise Goerlitz(Robert Koch Institute), Sabrina Bacci(European Centre for Disease Prevention and Control), Charlene Bennett(University College Dublin), Vesna Višekruna Vučina(Hrvatski zavod za javno zdravstvo), Alessandra Falchi(Université de Corse Pascal Paoli), Neus Latorre‐Margalef(Public Health Agency of Sweden), Camino Trobajo‐Sanmartín(Instituto de Salud Pública de Navarra), Joan O’Donnell(Health Service Executive), Noémie Sève(Inserm), Iván Martínez‐Baz(Instituto de Salud Carlos III), Maja Ilić(Hrvatski zavod za javno zdravstvo), Aurora López(Generalitat Valenciana), Ivan Mlinarić(Hrvatski zavod za javno zdravstvo), Anna Sara Carnahan(Public Health Agency of Sweden)
Influenza and Other Respiratory Viruses
January 1, 2024
Cited by 28


Related Papers